Page 1

Dvysr® Interim report January - September 2021 Continued focus on increased direct sales Third quarter , July - September 2021 Net sales amounted to SEK 24.3 million ( 16.5 ) corresponding to an increase by 47.4 percent . Adjusted for exchange rate changes , net sales increased by 49.7 percent . Gross profit totaled SEK 19.1 million ( 11.1 ) , corresponding to a gross margin of 78.5 percent ( 67.5 ) . Operating loss ( EBIT ) amounted to SEK -2.5 million ( -0.1 ) . Loss after tax totaled SEK -3.6 million ( -0.8 ) . Earnings per share before and after dilution amounted to SEK -0.32 ( -0.09 ) . Cash flow from operating activities amounted to -3.2 million ( 0.2 ) . Important events during the quarter Extraordinary General Meeting , September 30 At an Extraordinary General Meeting on September 30 , Pia Gideon was elected as a new member of the Board . Pia Gideon has long experience from different senior positions in Sweden and internationally within marketing , communication and leadership development . She is since 20 years active as Chair of the Board and Board of Directors in both listed companies as well as government - owned companies , with a speciality towards technology and health / healthcare . Strengthening of the management In July , the management group was strengthened by the recruitment of Sabina Berlin as CFO and Göran Rydin as COO . Sabina Berlin has solid experience from listed growth companies with associated financial reporting , process development and regulatory compliance . Göran Rydin has over 25 years of experience from leading positions within medtech with focus on research , development , project management , QA / Reg and production . Ulf Klangby , the founder of Devyser and former CEO , was appointed deputy CEO in July . Period January - September 2021 Net sales amounted to SEK 69.0 million ( 47.9 ) , corresponding to an increase by 43.9 percent . Adjusted for exchange rate changes , net sales increased by 49.5 percent . Gross profit totaled SEK 53.5 million ( 33.8 ) , corresponding to a gross margin of 77.5 percent ( 70.6 ) . Operating loss ( EBIT ) amounted to SEK -7.3 million ( -0.8 ) . Loss after tax totaled SEK - 10.1 million ( -2.7 ) . Earnings per share before and after dilution amounted to SEK -0.92 ( -0.31 ) . Cash flow from operating activities amounted to -10.6 million ( 5.6 ) . Share split and new share issue July 19 was the record date from the share split decided at the AGM , meaning that each existing share in the company was divided into 300 shares of the same class of shares . Before the share split , the number of shares in the company amounted to 37,516 and after the share split the number of shares amounted to 11,254,800 . In September , a new share issue was carried out in connection with the exercise of warrants which added SEK 3.3 million to the company . Building a sales organization in North America Planning and preparations for building a small sales organization in North America has been ongoing during the summer . A head of North American operations was recruited and began his employment August 1 , in the newly started US based subsidiary . Important events after the end of the quarter No important events has occured after the end of the quarter . Jul - Sep 2021 Jul - Sep 2020 Jan - Sep 2021 Jan - Sep 2020 Jan - Dec 2020 Key figures Net sales , SEK million Sales growth , % Gross margin , % EBITDA , SEK million EBITDA margin , % 24.3 16.5 69.0 47.9 65.7 47.4 13.6 43.9 3.1 2.2 78.5 67.5 77.5 70.6 71.6 -1.0 1.9 -2.9 5.2 1.7 Neg 11.5 Neg 10.9 2.6 Operating profit / loss ( EBIT ) , SEK million -2.5 -0.1 -7.3 -0.8 -10.9 Operating margin ( EBIT margin ) , % Neg Neg Neg Neg Neg -3.6 -0.8 -10.1 -2.7 -10.9 Profit / loss after tax , SEK million -3.2 0.2 -10.6 5.6 0.6 Cash flow from operating activities , SEK million 111.6 15.7 111.6 15.7 12.3 Available liquidity , SEK million -92.2 11.2 -92.2 11.2 13.2 Net cash ( - ) / Net debt ( + ) , SEK million 79.1 49.7 79.1 49.7 41.4 Equity ratio , % Neg Neg Neg Neg Neg Return on equity , % Devyser Diagnostics AB ( publ ) INTERIM REPORT JANUARY - SEPTEMBER 2021 1